Search

Your search keyword '"Jonathan Wadsley"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Jonathan Wadsley" Remove constraint Author: "Jonathan Wadsley"
124 results on '"Jonathan Wadsley"'

Search Results

1. Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series

2. Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases

3. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaResearch in context

4. Mental health burden for NHS healthcare staff during the COVID-19 pandemic: First results of a longitudinal survey

6. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

7. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model

8. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY)

9. Quality of Life in Post-Surgical Hypoparathyroidism (PoSH) in Thyroid and Parathyroid Surgery

11. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

17. Systematic review of health-related quality of life following thyroid cancer

18. Computed Tomographic Sarcopenia in Pancreatic Cancer: Further Utilization to Plan Patient Management

19. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

21. Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy

23. Medullary Thyroid Cancer Patient’s Assessment of Quality of Life Tools: Results from the QaLM Study

24. CTRad 10 Years On: From 10-point Plan to Top 10 Achievements

25. Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians

26. Investigating the Clinical Benefit of Selumetinib in Resensitising Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy: Results of the SEL-I-METRY Phase II Trial

27. Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial

28. Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy

29. Digital Detection of Sarcopenia in Pancreatic Cancer: Additional Utilization to Plan Patient Management

30. Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature

31. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL)

32. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

33. Long Term Outcomes and Exploratory Analyses of the Randomised Phase 3 BILCAP Study

34. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply

35. Molecular Radiotherapy Comes of Age

36. PancREatic Cancer and Individualised Supervised Exercise (PRECISE): a feasibility trial protocol for patients with resectable pancreatic ductal adenocarcinoma

37. Radiotherapy trial set-up in the UK: identifying inefficiencies and potential solutions

38. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

39. Optimising Chemotherapy for Frail and Older Patients With Advanced Gastroesophageal Cancer: The GO2 Phase III Trial

40. FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

41. Hypofractionated radiotherapy to the pancreas: U.K. experience

42. Genomic loss of heterozygosity and survival in the REAL3 trial

43. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer

44. ESPAC-5F: Four arm, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer

45. ESPAC-4: A randomized controlled phase III trial of adjuvant gemcitabine (GEM) and capecitabine (CAP) versus gemcitabine in resected pancreatic ductal adenocarcinoma: five year follow up

47. A pragmatic assessment of the British Thyroid Association 'U classification' of thyroid nodules with a focus on their follow-up

48. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

49. OWE-29 Can digital skeletal muscle index predict palliative chemotherapy uptake before patients undergo endoscopic pancreatic biopsy?

50. Efficacy of somatostatin analogues in managing hypercalcaemia due to PTHrP in a well differentiated metastatic pancreatic neuroendocrine tumour and discussion of modern treatment options: A clinical case

Catalog

Books, media, physical & digital resources